What does FDA now require when an AI or ML model is used in a GxP environment?
When an AI model is used in a GxP context — to support a release decision, quality analysis, or regulatory submission — it is subject to standard CSV requirements for the platform hosting it plus additional AI-specific requirements: a documented context of use, a risk-proportionate credibility assessment, training data qualification, bias controls, and ongoing monitoring for model drift. Unlike traditional validated systems, AI validation is explicitly continuous — a model may require revalidation if its predictive performance degrades after deployment.
Most of the industry conversation about AI in pharma has focused on using AI to generate validation documents faster. That's a narrow use case. The much larger regulatory question — and the one FDA and EMA are now actively answering — is: when AI is the system being validated, what does that validation actually require? The January 2026 joint publication sets the framework. Here is what it means in practice.
The January 2026 Regulatory Position: What Was Published
On 14 January 2026, FDA and EMA jointly published ten Guiding Principles of Good AI Practice in Drug Development — the first coordinated transatlantic regulatory position on how AI must be governed across the pharmaceutical lifecycle. These are not binding regulations yet, but they represent formal regulatory expectation and will underpin future binding guidance in both jurisdictions.
Where Traditional CSV Falls Short for AI
Standard GAMP 5-aligned CSV validates the software container — the platform, the interface, the data flows. It does not validate the model inside it. A trained ML model has a fundamentally different failure mode than a deterministic software function: it can pass IQ/OQ/PQ perfectly and still degrade silently in production as the data it receives shifts away from its training distribution. That failure mode does not appear in a traditional test script.
| Validation Dimension | Traditional CSV (GAMP 5) | AI/ML Model Validation |
|---|---|---|
| What is validated | Software functions against specified requirements | Model predictions against performance acceptance criteria on independent test data |
| Training data | Not applicable | Must be qualified — provenance documented, bias assessed across relevant subgroups |
| Failure mode | Deterministic — function either works or doesn't | Probabilistic — performance degrades gradually, may not be detectable without monitoring |
| Post-release obligation | Change control triggers re-assessment; periodic review confirms validated state | Continuous performance monitoring required; model drift triggers revalidation |
| Human oversight | Implied via SOPs and access controls | Explicitly required — human-in-the-loop checkpoint designed into the system for consequential decisions |
| Context of use | Intended use defined in URS | COU pre-specified and determines validation intensity; out-of-COU use is a validation deviation |
The Critical Concept: Context of Use
Context of use (COU) is the most operationally significant concept in the FDA's credibility framework for AI. It is the pre-specified, documented description of exactly how, where, and for what decision a model is intended to be used — including its outputs, their interpretation, their limits, and what happens when they fall outside acceptance criteria.
Why COU determines everything: The same model can have completely different validation requirements depending on its COU. A trend-detection model used to flag manufacturing deviations for human review (advisory output) faces lower validation intensity than the same model used to autonomously determine whether a batch should be released (consequential decision). The model architecture may be identical — the validation obligation is not.
FDA's January 2025 draft guidance — expected to be finalized in Q2/Q3 2026 — establishes a seven-step credibility assessment framework anchored to COU. If the COU changes after deployment (the model is used for a decision it was not validated for), that constitutes an out-of-scope use and triggers formal change control and likely revalidation.
Model Drift: The Post-Deployment Validation Problem
Model drift is what happens when the real-world data an AI model receives in production no longer matches the distribution it was trained on — and its predictive performance degrades as a result. In a GxP environment, this is not just a performance issue. It is a validation issue.
A process control model trained on sensor data from 2023 equipment may begin to underperform as equipment ages, raw material suppliers change, or operating conditions shift. If the model's outputs feed a quality decision, that degradation affects product quality without generating a traditional deviation — there is no failed test script, no error code, just quietly deteriorating predictions that the system accepts as valid. Detecting this requires pre-defined performance monitoring with statistical thresholds specified before deployment, not a manual check when something goes wrong.
The Regulatory Timeline
Where GoVal Fits
GoVal manages AI validation as an extension of the same lifecycle framework applied to all GxP computerized systems — with AI-specific fields built into the validation record. Context of use is a structured, mandatory field at system intake, not a free-text note. Training data qualification status is tracked alongside software version history. Performance acceptance criteria are linked to the monitoring plan, and when a post-deployment performance review flags a drift threshold breach, it generates a change control record with the same audit trail as any other GxP system change. The periodic review cycle includes model performance metrics alongside traditional validation state — so the system stays continuously inspection-ready under both existing GxP frameworks and the incoming AI-specific regulatory requirements.
Related Topics
Frequently Asked Questions
What did the FDA and EMA publish about AI in January 2026? +
What is 'context of use' in FDA AI validation? +
Does traditional CSV cover AI and ML models in GxP systems? +
What is model drift and why does it matter for GxP AI validation? +
What does 'human-in-the-loop' mean for GxP AI systems? +
Does the EU AI Act apply to pharma AI systems in GxP environments? +
Manage AI model validation alongside your full GxP programme
Context of use, credibility assessment, drift monitoring, and change control — AI validation in GoVal.